Development and clinical application of [11C]Verapamil-PET, a surrogate marker on p-glycoprotein expression

Efficacy of (R)-[11C] Verapamil-PET in diagnosis of Epilepsy(Year-Two)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000994

Enrollment

Registered

2014-01-23

Start date

2013-10-08

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Normal controls, patients with drug-resistant epilepsy and patients with drug-sensitive epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy controls ( age range 20-45 years) patient age (> 15), diagnose as epilepsy

Exclusion criteria

Exclusion criteria: Subjects who take medicines that affect on the function of p-glycoproteins Pregnancy or subject who feed the breast milk Subjects who had severe renal disease or liver disease Subjects who need treated by immunosuppressant or take immunosuppressant

Design outcomes

Primary

Measure	Time frame
Efficacy of assessing p-glycoprotein expression in patients with epilepsy through [11C]-verapamil PET	—

Secondary

Measure	Time frame
Side effect of cyclosporine, safety of [11C]-verapamil PET	—

Countries

Korea, Republic of

Contacts

Public ContactJung-Won Shin

Seoul National University Hospital

Outcome results